Table 1 Baseline characteristics
Exacerbation group(n = 162) | Control group(n = 32) | P | |||
|---|---|---|---|---|---|
Characteristic | PEF + symptom group(n = 98) | PEF group(n = 13) | Symptom group(n = 51) | ||
Gender | 0.141 | ||||
male | 77(78.6%) | 11(84.6%) | 37(72.5%) | 19(59.3%) | |
female | 21(21.4%) | 2(15.4%) | 14(27.5%) | 13(40.7) | |
Age, mean ± SD, y | 9.56 ± 2.08 | 10.69 ± 2.39 | 9.41 ± 3.03 | 9 ± 2.78 | 0.228 |
6–9 | 49(50%) | 4(30.8%) | 35(68.6%) | 16(50%) | |
10–14 | 41(41.8%) | 6(46.2%) | 13(25.5%) | 4(12.5%) | |
15–18 | 8(8.2%) | 3(23.1%) | 3(5.9%) | 12(37.5%) | |
Allergy history | 0.698 | ||||
Yes | 64(65.3%) | 10(76.9%) | 38(74.5%) | 22(68.8%) | |
No | 34(34.7%) | 3(23.1%) | 13(25.5%) | 10(31.2%) | |
Resident Region | 0.0001 | ||||
East China | 25(25.5%) | 10(76.9%) | 37(72.5%) | 26(81.3%) | |
West China | 71(72.4%) | 1(7.7%) | 10(19.6%) | 0 | |
Central China | 2(2.1%) | 2(15.4%) | 4(7.9%) | 6(18.7%) | |
Baseline PEF(l/min, ±2SD) | 237.73 ± 75.93 | 270.08 ± 83.04 | 239.53 ± 100.69 | 215.31 ± 87.64 | 0.014* |
Baseline Medication | 0.366 | ||||
LABA + ICS | 69(70.4%) | 8(61.5%) | 37(72.5%) | 20(62.5%) | |
ICS | 15(15.3%) | 1(7.7%) | 8(15.7%) | 3(9.4%) | |
others* | 14(14.3%) | 4(30.8%) | 6(11.8%) | 9(28.1%) | |